Cargando…
Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing
Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (...
Autores principales: | Elshabrawy, Hatem A., Coughlin, Melissa M., Baker, Susan C., Prabhakar, Bellur S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503966/ https://www.ncbi.nlm.nih.gov/pubmed/23185609 http://dx.doi.org/10.1371/journal.pone.0050366 |
Ejemplares similares
-
Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential
por: Coughlin, Melissa M., et al.
Publicado: (2011) -
Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms
por: Coughlin, Melissa M., et al.
Publicado: (2009) -
BROADLY NEUTRALIZING ANTIBODIES FROM HUMAN SURVIVORS TARGET A CONSERVED SITE IN THE EBOLA VIRUS GLYCOPROTEIN HR2/MPER REGION
por: Flyak, Andrew I., et al.
Publicado: (2018) -
HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration
por: Lu, Ying, et al.
Publicado: (2023) -
Design of HR1 and HR2 synthetic peptide analogs: Characterization of their antiviral activities and their capacities to induce neutralizing antibodies
por: Mzoughi, Olfa, et al.
Publicado: (2013)